Compare GAIA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | PLRX |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.9M | 68.7M |
| IPO Year | 1999 | 2020 |
| Metric | GAIA | PLRX |
|---|---|---|
| Price | $1.89 | $1.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.50 | $2.67 |
| AVG Volume (30 Days) | 116.7K | ★ 694.7K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,500,000.00 | N/A |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $12.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.50 | N/A |
| 52 Week Low | $1.82 | $1.05 |
| 52 Week High | $6.39 | $1.95 |
| Indicator | GAIA | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 41.60 |
| Support Level | N/A | N/A |
| Resistance Level | $2.19 | $1.37 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 22.67 | 24.00 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. The company operates in a single reporting segment. Its revenues is derived from subscription fees for services related to streaming content to the members. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.